Second Genome

Second Genome Overview

Founded 2009
Founded
Status Private
Employees 58
Employees
Latest Deal Type Grant
Latest Deal Amount $1.13M
Latest Deal Amount
Investors 15

Second Genome General Information

Description

Provider of microbial profiling services designed to develop improved ways for treating chronic disease and illness. The company's microbiome data platform utilizes microbiome biology, bioinformatics, computation and machine learning to identify prospective therapeutic lead candidates, bacteria, peptides and metabolites which benefit human health, enabling therapeutic candidates to be advanced through pharmaceutical clinical programs.

Contact Information

Formerly Known As
Phylotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 341 Allerton Avenue
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Second Genome Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 01-Jan-2019 $1.13M 000.00 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series B) 13-Apr-2016 000.00 000.00 0000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 07-Jun-2013 000.00 000.00 000.00 Completed Startup
2. Early Stage VC (Series A) 09-Aug-2011 $5M $6.24M 000.00 Completed Startup
1. Seed Round 07-Jul-2010 $1.24M $1.24M 00.00 Completed Startup

Second Genome Cap Table

To view Second Genome‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed 5,607,290 $0.000100 $0.02 $0.22 $0.22 1x $0.22 2.12%

Second Genome Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Pendulum Therapeutics Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
000000000 Venture Capital-Backed Vancouver, Canada 000 00000 00000000000 00000
00000000 000000 Venture Capital-Backed Emeryville, CA 000 00000 00000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 0000000000 00000
00000 000000000000 Venture Capital-Backed Somerville, MA 00 00000 00000000000 00000

Second Genome Executive Team (15)

Name Title Board Seat Contact Info
Todd DeSantis Co-Founder and Vice President of Informatics
Karim Dabbagh Ph.D President, Chief Executive Officer & Board Member
Anupama Hoey Chief Business Officer
Gary Andersen Ph.D Co-Founder & Advisor
Corey Goodman Ph.D Co-Founder & Chairman

10 Former Executives

Second Genome Board Members (13)

To view Second Genome‘s full board member team, request access »
Name Representing Role Since
Bradley Margus Self Board Member 000 0000
Carole Nuechterlein JD Roche Venture Fund Board Member 000 0000
Corey Goodman Ph.D Self Co-Founder & Chairman 000 0000
Elaine Jones Ph.D Pfizer Ventures Board Member 000 0000
Geoffrey Smith JD Digitalis Ventures Board Observer 000 0000

3 Former Board Members

Second Genome Investors (15)

To view Second Genome‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
U.S. Department of Health and Human Services Government 000 0000 000000 0
Digitalis Ventures Venture Capital Minority 000 0000 000000 0
Lifeforce Capital Venture Capital Minority 000 0000 000000 0
Lifeforce Ventures Venture Capital Minority 000 0000 000000 0
Lightstone Ventures Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial